Back to top
more

BeyondSpring (BYSI)

(Delayed Data from NSDQ)

$2.34 USD

2.34
28,629

+0.07 (3.08%)

Updated Jul 12, 2024 03:59 PM ET

After-Market: $2.34 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BYSI

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

BeyondSpring Inc. [BYSI]

Reports for Purchase

Showing records 21 - 40 ( 67 total )

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

06/02/2021

Company Report

Pages: 6

We See Smooth Sailing for Plinabulin in CIN with FDA; Priority Review Granted, Breakthrough Designation Already in Hand

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

04/30/2021

Company Report

Pages: 6

2020 Results; Project Plinabulin Approval, But Launch, Financial, and Clinical Risk Remain; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

04/05/2021

Company Report

Pages: 5

Sea Change in Risk Profile; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

11/24/2020

Company Report

Pages: 7

Plinabulin Answers the Breakthrough Designation Call; Target Adjusted to $43

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

09/08/2020

Daily Note

Pages: 5

Plinabulin Profile Rewarded with Breakthrough Therapy Designation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

09/03/2020

Company Report

Pages: 7

2Q Results; The Pins Are Set up; Plinabulin Has Started to Knock ''em Down

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

06/15/2020

Company Report

Pages: 7

Not a Bad Monday at All; PROTECTIVE-2 Planned Interim Hits Primary and Secondaries; Target Upped to $46

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

06/09/2020

Company Report

Pages: 7

Updated Phase 2 Data Further Strengthen Plinabulin''s Profile; Dose and Regimen Compliance Improved

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

04/30/2020

Company Report

Pages: 7

2019 Results; NDA Submissions and Upcoming Pivotal Data on Track

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

04/29/2020

Company Report

Pages: 6

Pioneering Effort Continues; FDA Agrees to Change Focusing on Superiority of Plinabulin

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

03/30/2020

Company Report

Pages: 7

Rolling NDA Begins in China as Expected; Target Adjusted to $30

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

03/25/2020

Company Report

Pages: 7

Endgame Starting Soon; Plinabulin Market Differentiation Important

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

02/24/2020

Company Report

Pages: 8

Plinabulin Data - Filing(s) Are Coming

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

12/18/2019

Company Report

Pages: 7

2020 Is the Year of Filings; 3Q19 Results

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

10/23/2019

Daily Note

Pages: 6

Study 106 Finally Gets Going to Potentially Broaden Scope of Plinabulin in CIN Significantly

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

09/24/2019

Company Report

Pages: 8

Plinabulin Effective in Breast Cancer

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

09/18/2019

Company Report

Pages: 6

2Q19 Results; Data and Filings Approaching Quickly

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

08/27/2019

Company Report

Pages: 8

Head-Head Plinabulin vs. Pegfilgrastim QOL

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

08/16/2019

Company Report

Pages: 21

A New Approach to Cancer Chemo Care

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 75.00

Research Provided by a Third Party

Company: BeyondSpring Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

07/10/2019

Company Report

Pages: 6

1Q19 Results; Awaiting Data and NDAs; Target Reduced to $41

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party